HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

True Religion

This article was originally published in The Rose Sheet

Executive Summary

Apparel company has inked a deal with Selective Fragrances to create men's and women's scents for launch in 2008, firms announce Aug. 1. The two fragrances will capture the clothing brand's "spirit of California bohemian chic," True Religion Chair and CEO Jeffrey Lubell says. "Selective's breadth of knowledge and artistic vision made a great impression on our team, and they now have a rich palette of almost two dozen potential scents in preliminary development stages," he notes. Givaudan will develop the True Religion signature fragrances. Terms of the deal require Selective Beauty to spend roughly 20% of sales on direct consumer advertising and marketing, with the ad campaign kicking off in fall 2008. Scent will be sold in True Religion doors and department stores including Saks Fifth Avenue, Nordstrom, Neiman Marcus, Bloomingdales and Barneys, as well as Sephora, Ulta and more than 1,000 specialty stores. There also will be international distribution and a presence in duty-free stores in the U.S. and Caribbean, firms say...

You may also be interested in...



US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014910

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel